
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Researchers in Japan are quantifying different types of melanin in depigmented and repigmented patches of vitiligo following psoralen plus ultraviolet A (PUVA) therapy.